Overview of serological techniques for influenza vaccine evaluation: Past, Present and Future

Vaccines

Volumn 2, Issue 4, 2014, Pages 707-734

  Trombetta, Claudia Maria ^a   Perini, Daniele ^b   Mather, Stuart ^c   Temperton, Nigel ^c   Montomoli, Emanuele ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b VisMederi Srl   (Italy)

^c UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Antibody titres; Correlates of protection; EMA criteria

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS SIALIDASE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN MEDICINES AGENCY; HEMAGGLUTINATION INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PROTECTION; PSEUDOTYPING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; SEROLOGY; SINGLE RADIAL HAEMOLYSIS; VIRUS NEUTRALIZATION;

EID: 84908251120     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2040707     Document Type: Review

References (163)

1. Hilleman, M.R. Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control. Vaccine 2002, 20, 3068-3087.
2. Van Essen, G.A.; Palache, A.M.; Forleo, E.; Fedson, D.S. Influenza vaccination in 2000: Recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003, 21, 1780-1785.
3. Centers for Disease Control and Prevention (CDC). Prevention and control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5208a1.htm (accessed on 04 November 2013).
4. Monto, A.S. Vaccines and antiviral drugs in pandemic preparedness. Emerg. Infect. Dis. 2006, 12, 55-60.
5. Fedson, D.S.; Opal, S.M. The controversy over H5N1 transmissibility research: An opportunity to define a practical response to a global threat. Hum. Vaccin. Immunother. 2013, 9, 977-986.
6. Geeraedts, F.; Saluja, V.; ter Veer, W.; Amorij, J.P.; Frijlink, H.W.; Wilschut, J.; Hinrichs, W.L.; Huckriede, A. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J. 2010, 12, 215-222.
7. Onions, D.; Egan, W.; Jarrett, R.; Novicki, D.; Gregersen, J.P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010, 38, 544-551.
8. Montomoli, E.; Capecchi, B.; Hoschler, K. Correlates of Protection against Influenza. In Influenza Vaccines for the Future; Schmidt, A., Weber, O., Kaufmann, S.H.E., Eds.; Springer: Basel, Switaland, 2011.
9. Beyer, W.E.; Palache, A.M.; de Jong, J.C.; Osterhaus, A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: Systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20, 1340-1353.
10. Cox, R.J.; Brokstad, K.A.; Ogra, P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59, 1-15.
11. Hobson, D.; Curry, R.L.; Beare, A.S.; Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 1972, 70, 767-777.
12. Coudeville, L.; Bailleux, F.; Riche, B.; Megas, F.; Andre, P.; Ecochard, R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: Development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 2010, doi:10.1186/1471-2288-10-18.
13. Howard, M.K.; Sabarth, N.; Savidis-Dacho, H.; Portsmouth, D.; Kistner, O.; Kreil, T.R.; Ehrlich, H.J.; Barrett, P.N. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011, 6, e23791.
14. Gross, P.A.; Davis, A.E. Neutralization test in influenza: Use in individuals without hemagglutination inhibition antibody. J. Clin. Microbiol. 1979, 10, 382-384.
15. Stephenson, I.; Heath, A.; Major, D.; Newman, R.W.; Hoschler, K.; Junzi, W.; Katz, J.M.; Weir, J.P.; Zambon, M.C.; Wood, J.M. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg. Infect. Dis. 2009, 15, 1252-1259.
16. Couch, R.B.; Atmar, R.L.; Keitel, W.A.; Quarles, J.M.; Wells, J.; Arden, N.; Nino, D. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012, 31, 190-195.
17. Sultana, I.; Yang, K.; Getie-Kebtie, M.; Couzens, L.; Markoff, L.; Alterman, M.; Eichelberger, M.C. Stability of neuraminidase in inactivated influenza vaccines. Vaccine 2014, 32, 2225-2230.
18. Van Assen, S.; de Haan, A.; Holvast, A.; Horst, G.; Gorter, L.; Westra, J.; Kallenberg, C.G.; Telgt, D.S.; Palache, A.M.; Giezeman, K.M.; et al. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. Clin. Immunol. 2011, 141, 161-168.
19. Skowronski, D.M.; Hottes, T.S.; McElhaney, J.E.; Janjua, N.Z.; Sabaiduc, S.; Chan, T.; Gentleman, B.; Purych, D.; Gardy, J.; Patrick, D.M.; et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: Higher antibody and lower cell-mediated immune responses with advanced age. J. Infect. Dis. 2011, 203, 158-167.
20. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines; The European Agency for the Evaluation of Medicinal Products (EMEA): London, UK, 1996.
21. Center for Disease Control and Prevention. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm (accessed on 4 November 2013).
22. McCullers, J.A.; Huber, V.C. Correlates of vaccine protection from influenza and its complications. Hum. Vaccin. Immunother. 2012, 8, 34-44.
23. Rothberg, M.B.; Haessler, S.D.; Brown, R.B. Complications of viral influenza. Am. J. Med. 2008, 121, 258-264.
24. Plotkin, S.A.; Gilbert, P.B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 2012, 54, 1615-1617.
25. Qin, L.; Gilbert, P.B.; Corey, L.; McElrath, M.J.; Self, S.G. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 2007, 196, 1304-1312.
26. Hannoun, C.; Megas, F.; Piercy, J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004, 103, 133-138.
27. Fox, J.P.; Cooney, M.K.; Hall, C.E.; Foy, H.M. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am. J. Epidemiol. 1982, 116, 228-242.
28. Ng, S.; Fang, V.J.; Ip, D.K.; Chan, K.H.; Leung, G.M.; Peiris, J.S.; Cowling, B.J. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J. Infect. Dis. 2013, 208, 1320-1324.
29. Plotkin, S.A. Vaccines: Correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47, 401-409.
30. Plotkin, S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010, 17, 1055-1065.
31. Chen, R.T.; Orenstein, W.A. Epidemiologic methods in immunization programs. Epidemiol. Rev. 1996, 18, 99-117.
32. Dunning, A.J. A model for immunological correlates of protection. Stat. Med. 2006, 25, 1485-1497.
33. Centers for Disease Control and Prevention (CDC). Flu Vaccine Effectiveness: Questions and Answers for Health Professionals. Available online: http://www.cdc.gov/flu/professionals/ vaccination/effectivenessqa.htm (accessed on 10 November 2013).
34. Halloran, M.E.; Longini, I.M., Jr.; Struchiner, C.J. Surrogates of Protection. In Design and Analysis of Vaccine Studies; Springer: New York, USA, 2009.
35. Sadoff, J.C.; Wittes, J. Correlates, surrogates, and vaccines. J. Infect. Dis. 2007, 196, 1279-1281.
36. Cross, G. Hemagglutination inhibition assays. Semin. Avian Exotic Pet Med. 2002, 11, 15-18.
37. World Health Organization (WHO). Manual for the laboratory diagnosis and virological surveillance of influenza. 2011; Available online: http://whqlibdoc.who.int/publications/2011/ 9789241548090_eng.pdf (accessed on 10 November 2013).
38. Nauta, J.J.; Beyer, W.E.; Osterhaus, A.D. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 2009, 37, 216-221.
39. De Jong, J.C.; Palache, A.M.; Beyer, W.E.; Rimmelzwaan, G.F.; Boon, A.C.; Osterhaus, A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. (Basel) 2003, 115, 63-73.
40. Noah, D.L.; Hill, H.; Hines, D.; White, E.L.; Wolff, M.C. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin. Vaccine Immunol. 2009, 16, 558-566.
41. Black, S.; Nicolay, U.; Vesikari, T.; Knuf, M.; del Giudice, G.; della Cioppa, G.; Tsai, T.; Clemens, R.; Rappuoli, R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 2011, 30, 1081-1085.
42. Ambrose, C.S. Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults. Expert Rev. Vaccines 2011, 10, 1127-1130.
43. Granstrom, M.; Voordouw, A.C. Registration of influenza vaccines for children in Europe. Vaccine 2011, 29, 7572-7575.
44. Cosma, A.; Buhler, S.; Nagaraj, R.; Staib, C.; Hammarin, A.L.; Wahren, B.; Goebel, F.D.; Erfle, V.; Sutter, G. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin. Diagn. Lab. Immunol. 2004, 11, 406-410.
45. Van der Velden, M.V.; Aichinger, G.; Pollabauer, E.M.; Low-Baselli, A.; Fritsch, S.; Benamara, K.; Kistner, O.; Muller, M.; Zeitlinger, M.; Kollaritsch, H.; et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012, 30, 6127-6135.
46. Adamson, W.E.; McGregor, E.C.; Kavanagh, K.; McMenamin, J.; McDonagh, S.; Molyneaux, P.J.; Templeton, K.E.; Carman, W.F. Population exposure to a novel influenza A virus over three waves of infection. J. Clin. Virol. 2011, 52, 300-303.
47. Frank, A.L.; Puck, J.; Hughes, B.J.; Cate, T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 1980, 12, 426-432.
48. Harmon, M.W.; Rota, P.A.; Walls, H.H.; Kendal, A.P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J. Clin. Microbiol. 1988, 26, 333-337.
49. Ansaldi, F.; Bacilieri, S.; Amicizia, D.; Valle, L.; Banfi, F.; Durando, P.; Sticchi, L.; Gasparini, R.; Icardi, G.; Crovari, P. Antigenic characterisation of influenza B virus with a new microneutralisation assay: Comparison to haemagglutination and sequence analysis. J. Med. Virol. 2004, 74, 141-146.
50. Rowe, T.; Abernathy, R.A.; Hu-Primmer, J.; Thompson, W.W.; Lu, X.; Lim, W.; Fukuda, K.; Cox, N.J.; Katz, J.M. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 1999, 37, 937-943.
51. Ehrlich, H.J.; Muller, M.; Oh, H.M.; Tambyah, P.A.; Joukhadar, C.; Montomoli, E.; Fisher, D.; Berezuk, G.; Fritsch, S.; Low-Baselli, A.; et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 2008, 358, 2573-2584.
52. Veguilla, V.; Hancock, K.; Schiffer, J.; Gargiullo, P.; Lu, X.; Aranio, D.; Branch, A.; Dong, L.; Holiday, C.; Liu, F.; et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J. Clin. Microbiol. 2011, 49, 2210-2215.
53. Sui, J.; Hwang, W.C.; Perez, S.; Wei, G.; Aird, D.; Chen, L.M.; Santelli, E.; Stec, B.; Cadwell, G.; Ali, M.; et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16, 265-273.
54. Miller, E.; Hoschler, K.; Hardelid, P.; Stanford, E.; Andrews, N.; Zambon, M. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010, 375, 1100-1108.
55. Hakim, H.; Allison, K.J.; van de Velde, L.A.; Li, Y.; Flynn, P.M.; McCullers, J.A. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 2012, 30, 879-885.
56. Huber, V.C.; McKeon, R.M.; Brackin, M.N.; Miller, L.A.; Keating, R.; Brown, S.A.; Makarova, N.; Perez, D.R.; Macdonald, G.H.; McCullers, J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13, 981-990.
57. Stephenson, I.; Das, R.G.; Wood, J.M.; Katz, J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative study. Vaccine 2007, 25, 4056-4063.
58. World Health Organization (WHO). Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases, 2007. Available online: http://www.who.int/influenza/resources/documents/RecAIlabtestsAug07.pdf (accessed on 11 November 2013).
59. Cox, R.J.; Pedersen, G.; Madhun, A.S.; Svindland, S.; Saevik, M.; Breakwell, L.; Hoschler, K.; Willemsen, M.; Campitelli, L.; Nostbakken, J.K.; et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 2011, 29, 8049-8059.
60. +T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 2009, 106, 3877-3882.
61. Allwinn, R.; Geiler, J.; Berger, A.; Cinatl, J.; Doerr, H.W. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: How is the prevalence rate of protecting antibodies in humans? Med. Microbiol. Immunol. 2010, 199, 117-121.
62. Hancock, K.; Veguilla, V.; Lu, X.; Zhong, W.; Butler, E.N.; Sun, H.; Liu, F.; Dong, L.; DeVos, J.R.; Gargiullo, P.M.; et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 2009, 361, 1945-1952.
63. Stephenson, I.; Wood, J.M.; Nicholson, K.G.; Charlett, A.; Zambon, M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004, 103, 91-95.
64. Kayali, G.; Setterquist, S.F.; Capuano, A.W.; Myers, K.P.; Gill, J.S.; Gray, G.C. Testing human sera for antibodies against avian influenza viruses: Horse RBC hemagglutination inhibition vs. microneutralization assays. J. Clin. Virol. 2008, 43, 73-78.
65. Okuno, Y.; Tanaka, K.; Baba, K.; Maeda, A.; Kunita, N.; Ueda, S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J. Clin. Microbiol. 1990, 28, 1308-1313.
66. Leroux-Roels, I.; Leroux-Roels, G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 2009, 8, 401-423.
67. Temperton, N.J.; Hoschler, K.; Major, D.; Nicolson, C.; Manvell, R.; Hien, V.M.; Do, Q.H.; de Jong, M.; Zambon, M.; Takeuchi, Y.; et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 2007, 1, 105-112.
68. Garcia, J.M.; Lai, J.C. Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: An update. Expert Rev. Anti Infect. Ther. 2011, 9, 443-455.
69. Molesti, E.; Milani, A.; Terregino, C.; Cattoli, G.; Temperton, N.J. Comparative serological assays for the study of H5 and H7 avian influenza viruses. Influenza Res. Treat. 2013, doi:10.1155/2013/286158.
70. Bottcher, E.; Matrosovich, T.; Beyerle, M.; Klenk, H.D.; Garten, W.; Matrosovich, M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006, 80, 9896-9898.
71. Ferrara, F.; Molesti, E.; Bottcher-Friebertshauser, E.; Cattoli, G.; Corti, D.; Scott, S.D.; Temperton, N.J. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J. Mol. Genet. Med. 2012, 7, 309-314.
72. Scott, S.; Molesti, E.; Temperton, N.; Ferrara, F.; Bottcher-Friebertshauser, E.; Daly, J. The use of equine influenza pseudotypes for serological screening. J. Mol. Genet. Med. 2012, 6, 304-308.
73. Molesti, E.; Wright, E.; Terregino, C.; Rahman, R.; Cattoli, G.; Temperton, N. Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J. Immunol. Res. 2014, doi:10.1155/2014/457932.
74. Alberini, I.; del Tordello, E.; Fasolo, A.; Temperton, N.J.; Galli, G.; Gentile, C.; Montomoli, E.; Hilbert, A.K.; Banzhoff, A.; del Giudice, G.; et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009, 27, 5998-6003.
75. Corti, D.; Suguitan, A.L., Jr.; Pinna, D.; Silacci, C.; Fernandez-Rodriguez, B.M.; Vanzetta, F.; Santos, C.; Luke, C.J.; Torres-Velez, F.J.; Temperton, N.J.; et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 2010, 120, 1663-1673.
76. Garcia, J.M.; Lagarde, N.; Ma, E.S.; de Jong, M.D.; Peiris, J.S. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J. Clin. Virol. 2010, 47, 29-33.
77. Garcia, J.M.; Pepin, S.; Lagarde, N.; Ma, E.S.; Vogel, F.R.; Chan, K.H.; Chiu, S.S.; Peiris, J.S. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 2009, 4, e7918.
78. Hultberg, A.; Temperton, N.J.; Rosseels, V.; Koenders, M.; Gonzalez-Pajuelo, M.; Schepens, B.; Ibanez, L.I.; Vanlandschoot, P.; Schillemans, J.; Saunders, M.; et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 2011, 6, e17665.
79. Li, Z.; Ma, C.; Liu, Z.; He, W. Serologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtype H5N1 viruses in China. Immunol. Lett. 2011, 135, 59-63.
80. Wang, W.; Butler, E.N.; Veguilla, V.; Vassell, R.; Thomas, J.T.; Moos, M., Jr.; Ye, Z.; Hancock, K.; Weiss, C.D. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods 2008, 153, 111-119.
81. Corti, D.; Voss, J.; Gamblin, S.J.; Codoni, G.; Macagno, A.; Jarrossay, D.; Vachieri, S.G.; Pinna, D.; Minola, A.; Vanzetta, F.; et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333, 850-856.
82. Kaminski, D.A.; Lee, F.E. Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. Front. Immunol. 2011, 2, doi:10.3389/fimmu.2011.00076.
83. Hai, R.; Krammer, F.; Tan, G.S.; Pica, N.; Eggink, D.; Maamary, J.; Margine, I.; Albrecht, R.A.; Palese, P. Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes. J. Virol. 2012, 86, 5774-5781.
84. Mallajosyula, V.V.; Citron, M.; Ferrara, F.; Lu, X.; Callahan, C.; Heidecker, G.J.; Sarma, S.P.; Flynn, J.A.; Temperton, N.J.; Liang, X.; et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. USA 2014, 111, E2514-E2523.
85. Molesti, E.; Ferrara, F.; Lapini, G.; Montomoli, E.; Temperton, N. Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals. Biomed. Res. Int. 2014, doi:10.1155/2014/231365.
86. Schild, G.C.; Pereira, M.S.; Chakraverty, P. Single-radial-hemolysis: A new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull. World Health Organ. 1975, 52, 43-50.
87. Russell, S.M.; McCahon, D.; Beare, A.S. A single radial haemolysis technique for the measurement of influenza antibody. J. Gen. Virol. 1975, 27, 1-10.
88. Morley, P.S.; Hanson, L.K.; Bogdan, J.R.; Townsend, H.G.; Appleton, J.A.; Haines, D.M. The relationship between single radial hemolysis, hemagglutination inhibition, and virus neutralization assays used to detect antibodies specific for equine influenza viruses. Vet. Microbiol. 1995, 45, 81-92.
89. Chan, Y.C.; Tan, H.C.; Tan, S.H.; Balachandran, K. The use of the single radial haemolysis technique in the serological diagnosis of dengue and Japanese encephalitis virus infections. Bull. World Health Organ. 1985, 63, 1043-1053.
90. Oxford, J.S.; Yetts, R.; Schild, G.C. Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis. J. Hyg. (Lond.) 1982, 88, 325-333.
91. Fulton, R.E.; DiNinno, V.L.; Frank, R.I.; Fildes, J.; Turner, I.J. Single radial hemolysis test for quantitation of complement-fixing antibodies to non-hemagglutinating viruses. J. Clin. Microbiol. 1984, 20, 248-254.
92. Vaananen, P.; Hovi, T.; Helle, E.P.; Penttinen, K. Determination of mumps and influenza antibodies by haemolysis-in-gel. Arch. Virol. 1976, 52, 91-99.
93. Clarke, M.; Boustred, J.; Seagroatt, V.; Schild, G.C. The use of single-radial-haemolysis for rubella antibody studies. J. Hyg. (Lond.) 1977, 79, 355-364.
94. Russell, S.M.; Benjamin, S.R.; Briggs, M.; Jenkins, M.; Mortimer, P.P.; Payne, S.B. Evaluation of the single radial haemolysis (SRH) technique for rubella antibody measurement. J. Clin. Pathol. 1978, 31, 521-526.
95. Probert, M.; Russell, S.M. Measurement of parainfluenza-3 virus antibody by the single radial hemolysis technique. J. Clin. Microbiol. 1975, 2, 157-161.
96. Hierholzer, J.C.; Tannock, G.A. Quantitation of antibody to non-hemagglutinating viruses by single radial hemolysis: Serological test for human coronaviruses. J. Clin. Microbiol. 1977, 5, 613-620.
97. Wood, J.M.; Melzack, D.; Newman, R.W.; Major, D.L.; Zambon, M.; Nicholson, K.G.; Podda, A. A single radial haemolysis assay for antibody to H5 haemagglutinin. Int. Congr. Ser. 2001, 1219, 761-766.
98. Al-Khayatt, R.; Jennings, R.; Potter, C.W. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J. Hyg. (Lond.) 1984, 93, 301-312.
99. Callow, K.A.; Beare, A.S. Measurement of antibody to influenza virus neuraminidase by single radial hemolysis in agarose gels. Infect. Immun. 1976, 13, 1-8.
100. Joss, A.W.; McPherson, J.K.; Williams, H. Single radial haemolysis: A survey of antibody titres in the highland region of Scotland to recent strains of influenza A. J. Hyg. (Lond.) 1978, 80, 1-11.
101. Mancini, G.; Donatelli, I.; Arangio-Ruiz, G.; Rozera, C.; Macchia, T. Comparison of haemagglutination-inhibition and single radial haemolysis techniques for detecting antibodies to influenza A and B viruses. J. Hyg. (Lond.) 1983, 91, 157-162.
102. Wood, J.M.; Gaines-Das, R.E.; Taylor, J.; Chakraverty, P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12, 167-174.
103. Farrohi, K.; Farrohi, F.K.; Noble, G.R.; Kaye, H.S.; Kendal, A.P. Evaluation of the single radial hemolysis test for measuring hemagglutinin-and neuraminidase-specific antibodies to H3N2 influenza strains and antibodies to influenza B. J. Clin. Microbiol. 1977, 5, 353-360.
104. Nicholson, K.G.; Colegate, A.E.; Podda, A.; Stephenson, I.; Wood, J.; Ypma, E.; Zambon, M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357, 1937-1943.
105. Jia, N.; Wang, S.X.; Liu, Y.X.; Zhang, P.H.; Zuo, S.Q.; Lin, Z.; Dang, R.L.; Ma, Y.H.; Zhang, C.; Zhang, L.; et al. Increased sensitivity for detecting avian influenza-specific antibodies by a modified hemagglutination inhibition assay using horse erythrocytes. J. Virol. Methods 2008, 153, 43-48.
106. Stephenson, I.; Nicholson, K.G.; Colegate, A.; Podda, A.; Wood, J.; Ypma, E.; Zambon, M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21, 1687-1693.
107. Beran, J.; Abdel-Messih, I.A.; Raupachova, J.; Hobzova, L.; Fragapane, E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 2010, 32, 2186-2197.
108. Vesikari, T.; Forsten, A.; Herbinger, K.H.; Cioppa, G.D.; Beygo, J.; Borkowski, A.; Groth, N.; Bennati, M.; von Sonnenburg, F. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012, 30, 1388-1396.
109. Tambyah, P.A.; Wilder-Smith, A.; Pavlova, B.G.; Barrett, P.N.; Oh, H.M.; Hui, D.S.; Yuen, K.Y.; Fritsch, S.; Aichinger, G.; Loew-Baselli, A.; et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012, 30, 329-335.
110. Vesikari, T.; Karvonen, A.; Tilman, S.; Borkowski, A.; Montomoli, E.; Banzhoff, A.; Clemens, R. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126, e762-e770.
111. Nolan, T.; Richmond, P.C.; McVernon, J.; Skeljo, M.V.; Hartel, G.F.; Bennet, J.; Basser, R.L. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir. Viruses 2009, 3, 315-325.
112. Kilbourne, E.D.; Laver, W.G.; Schulman, J.L.; Webster, R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J. Virol. 1968, 2, 281-288.
113. Sylte, M.J.; Suarez, D.L. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 2009, 333, 227-241.
114. Kilbourne, E.D.; Couch, R.B.; Kasel, J.A.; Keitel, W.A.; Cate, T.R.; Quarles, J.H.; Grajower, B.; Pokorny, B.A.; Johansson, B.E. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13, 1799-1803.
115. Schulman, J.L.; Khakpour, M.; Kilbourne, E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J. Virol. 1968, 2, 778-786.
116. Naikhin, A.N.; Tsaritsina, I.M.; Oleinikova, E.V.; Syrodoeva, L.G.; Korchanova, N.L.; Denisov, G.M.; Shvartsman, Ya.S. The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis. J. Hyg. (Lond.) 1983, 91, 131-138.
117. Webster, R.G.; Laver, W.G.; Kilbourne, E.D. Reactions of antibodies with surface antigens of influenza virus. J. Gen. Virol. 1968, 3, 315-326.
118. Johansson, B.E.; Moran, T.M.; Bona, C.A.; Popple, S.W.; Kilbourne, E.D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 1987, 139, 2010-2014.
119. Chen, Z.; Kim, L.; Subbarao, K.; Jin, H. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 2012, 30, 2516-2522.
120. Sylte, M.J.; Hubby, B.; Suarez, D.L. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007, 25, 3763-3772.
121. Hassantoufighi, A.; Zhang, H.; Sandbulte, M.; Gao, J.; Manischewitz, J.; King, L.; Golding, H.; Straight, T.M.; Eichelberger, M.C. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010, 28, 790-797.
122. Lambre, C.R.; Terzidis, H.; Greffard, A.; Webster, R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J. Immunol. Methods 1990, 135, 49-57.
123. Report from Scientific Workshop on Serology Assays and Correlates of Protection for Influenza Vaccines; European Medicines Agency: London, UK, 2010.
124. Fritz, R.; Sabarth, N.; Kiermayr, S.; Hohenadl, C.; Howard, M.K.; Ilk, R.; Kistner, O.; Ehrlich, H.J.; Barrett, P.N.; Kreil, T.R. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J. Infect. Dis. 2012, 205, 28-34.
125. Gavrilov, V.; Orekov, T.; Alabanza, C.; Porika, U.; Jiang, H.; Connolly, K.; Pincus, S. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods 2011, 173, 364-373.
126. Kendal, A.P.; Bozeman, F.M.; Ennis, F.A. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun. 1980, 29, 966-971.
127. Monto, A.S.; Kendal, A.P. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973, 1, 623-625.
128. Easterbrook, J.D.; Schwartzman, L.M.; Gao, J.; Kash, J.C.; Morens, D.M.; Couzens, L.; Wan, H.; Eichelberger, M.C.; Taubenberger, J.K. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 2012, 432, 39-44.
129. Sandbulte, M.R.; Westgeest, K.B.; Gao, J.; Xu, X.; Klimov, A.I.; Russell, C.A.; Burke, D.F.; Smith, D.J.; Fouchier, R.A.; Eichelberger, M.C. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. USA 2011, 108, 20748-20753.
130. Rockman, S.; Brown, L.E.; Barr, I.G.; Gilbertson, B.; Lowther, S.; Kachurin, A.; Kachurina, O.; Klippel, J.; Bodle, J.; Pearse, M.; et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 2013, 87, 3053-3061.
131. Couch, R.B.; Kasel, J.A.; Gerin, J.L.; Schulman, J.L.; Kilbourne, E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J. Infect. Dis. 1974, 129, 411-420.
132. Powers, D.C.; Kilbourne, E.D.; Johansson, B.E. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol. 1996, 3, 511-516.
133. Sandbulte, M.R.; Jimenez, G.S.; Boon, A.C.; Smith, L.R.; Treanor, J.J.; Webby, R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007, 4, e59.
134. Brett, I.C.; Johansson, B.E. Immunization against influenza A virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005, 339, 273-280.
135. Johansson, B.E.; Matthews, J.T.; Kilbourne, E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16, 1009-1015.
136. Bosch, B.J.; Bodewes, R.; de Vries, R.P.; Kreijtz, J.H.; Bartelink, W.; van Amerongen, G.; Rimmelzwaan, G.F.; de Haan, C.A.; Osterhaus, A.D.; Rottier, P.J. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 2010, 84, 10366-10374.
137. Kilbourne, E.D.; Johansson, B.E.; Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA 1990, 87, 786-790.
138. Johansson, B.E.; Bucher, D.J.; Kilbourne, E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 1989, 63, 1239-1246.
139. Gamblin, S.J.; Skehel, J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 2010, 285, 28403-28409.
140. Schulman, J.L. The role of antineuraminidase antibody in immunity to influenza virus infection. Bull. World Health Organ. 1969, 41, 647-650.
141. Rappuoli, R. Bridging the knowledge gaps in vaccine design. Nat. Biotechnol. 2007, 25, 1361-1366.
142. Dormitzer, P.R.; Galli, G.; Castellino, F.; Golding, H.; Khurana, S.; del Giudice, G.; Rappuoli, R. Influenza vaccine immunology. Immunol. Rev. 2011, 239, 167-177.
143. Ashkar, S.; Weber, G.F.; Panoutsakopoulou, V.; Sanchirico, M.E.; Jansson, M.; Zawaideh, S.; Rittling, S.R.; Denhardt, D.T.; Glimcher, M.J.; Cantor, H. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000, 287, 860-864.
144. Yewdell, W.J.; Hackett, J.C. The Influenza Viruses. In The Viruses; Springer: New York, NY, USA, 1989.
145. Rimmelzwaan, G.F.; Nieuwkoop, N.; Brandenburg, A.; Sutter, G.; Beyer, W.E.; Maher, D.; Bates, J.; Osterhaus, A.D. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000, 19, 1180-1187.
146. Stambas, J.; Guillonneau, C.; Kedzierska, K.; Mintern, J.D.; Doherty, P.C.; la Gruta, N.L. Killer T cells in influenza. Pharmacol. Ther. 2008, 120, 186-196.
147. O’Neill, E.; Krauss, S.L.; Riberdy, J.M.; Webster, R.G.; Woodland, D.L. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J. Gen. Virol. 2000, 81, 2689-2696.
148. +T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012, 18, 274-280.
149. Thomas, P.G.; Keating, R.; Hulse-Post, D.J.; Doherty, P.C. Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 2006, 12, 48-54.
150. Zaiss, D.M.; Boog, C.J.; van Eden, W.; Sijts, A.J. Considerations in the design of vaccines that induce CD8 T cell mediated immunity. Vaccine 2010, 28, 7716-7722.
151. Yewdell, J.W.; Bennink, J.R.; Smith, G.L.; Moss, B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1985, 82, 1785-1789.
152. Murasko, D.M.; Bernstein, E.D.; Gardner, E.M.; Gross, P.; Munk, G.; Dran, S.; Abrutyn, E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 2002, 37, 427-439.
153. +T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 2013, 9, e1003207.
154. To, K.K.; Zhang, A.J.; Hung, I.F.; Xu, T.; Ip, W.C.; Wong, R.T.; Ng, J.C.; Chan, J.F.; Chan, K.H.; Yuen, K.Y. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin. Vaccine Immunol. 2012, 19, 1012-1018.
155. Jegaskanda, S.; Job, E.R.; Kramski, M.; Laurie, K.; Isitman, G.; de Rose, R.; Winnall, W.R.; Stratov, I.; Brooks, A.G.; Reading, P.C.; et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 2013, 190, 1837-1848.
156. Kuszewski, K.; Brydak, L. The epidemiology and history of influenza. Biomed. Pharmacother. 2000, 54, 188-195.
157. Calza, L.; Briganti, E.; Manfredi, R.; Chiodo, F. Influenza. Recent Prog. Med. 2000, 91, 657-666.
158. Hay, A.J.; Gregory, V.; Douglas, A.R.; Lin, Y.P. The evolution of human influenza viruses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1861-1870.
159. Han, T.; Marasco, W.A. Structural basis of influenza virus neutralization. Ann. NY Acad. Sci. 2011, 1217, 178-190.
160. Haber, M. Estimation of the direct and indirect effects of vaccination. Stat. Med. 1999, 18, 2101-2109.
161. Wu, J.; Fang, H.H.; Chen, J.T.; Zhou, J.C.; Feng, Z.J.; Li, C.G.; Qiu, Y.Z.; Liu, Y.; Lu, M.; Liu, L.Y.; et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: A phase II, double-blind, randomized trial. Clin. Infect. Dis. 2009, 48, 1087-1095.
162. Barrett, P.N.; Berezuk, G.; Fritsch, S.; Aichinger, G.; Hart, M.K.; El-Amin, W.; Kistner, O.; Ehrlich, H.J. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377, 751-759.
163. Guideline on Influenza Vaccines Prepared from Viruses with the Potential to Cause a Pandemic and Intended for Use Outside of the Core Dossier Context; Committee for Human Medical Products: London, UK, 2007